Introduction
Clinicians are concerned that treatment of rheumatoid arthritis (RA) with tumour necrosis factor alpha antagonists (TNFα biologics) may increase patients' risk of melanoma compared with treatment with nonbiologic disease-modifying antirheumatic drugs (nbDMARDS) [1] . Although most early studies evaluating the risk of melanoma in patients with RA irrespective of the type of treatment did not show an increased risk compared with the background population risk [2] , treatment regimens have evolved in recent decades and studies carried out more recently have reported a higher risk of melanoma in RA patients than in the general population [3, 4] . TNFα biologics were first introduced in 1998 [5] and registries have been established to examine biologic use and the risk of cancer [6] because of increased malignancy concerns.
RA patients treated with TNFα biologic therapy experience profound immunomodulation [7] and may thus be at an increased risk of melanoma, an immunogenic cancer, similar to solid organ transplant recipients or those with HIV/AIDS [8, 9] with compromised immunity. A meta-analysis carried out in 2011, pooling the results of only two available studies, reported a combined estimate of the risk of melanoma in RA patients treated with TNFα biologics versus biologics-naive patients of 1.79 [95% confidence interval (CI) 0.92-2.67] [6] . A metaanalysis of the risk of melanoma in nbDMARD-treated RA patients compared with the general population reported a pooled standardized incidence ratio (SIR) of 0.95 (95% CI 0.86-1.04) (n = 11 studies) [10] . That metaanalysis specifically excluded patient populations known to be exposed to TNFα biologics [11, 12] and thus showed that RA patients treated with nbDMARDS are not at an increased risk of melanoma compared with the general population. To date, there has been no combined analysis of estimates of the risk of melanoma in RA patients treated with TNFα biologics compared with the general population, and yet, this is needed so that comparisons with other patient populations treated with TNFα biologics, such as inflammatory bowel disease patients [13] , can be made. This systematic review and meta-analysis therefore aimed to synthesize the available evidence on the risk of melanoma in RA patients treated with TNFα biologics compared with those treated with nbDMARDS. A secondary aim was to quantify the risk of melanoma in TNFα biologics-treated RA patients compared with the general population.
Methods
The systematic review and meta-analysis was carried out in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines for reviews of observational studies [14] .
Data sources and searches
Eligible studies published between 1 January 1998 and January 2016 were identified by searching the Medline 1950 (US National Library of Medicine, Bethesda, Maryland, USA) database using PubMed software as the search interface; Embase 1966 database (Elsevier Science, Amsterdam, Holland) using the Embase search interface; and the ISI Science Citation Index using the ISI Web of Science search interface. We used the following medical subject headings terms or text words (both the USA and UK spellings): melanoma, cancer, neoplasms, rheumatoid arthritis, RA, rheumatic diseases, aetiology, cohort. Studies that had been cited commonly in the literature and review articles were also included as citation search terms in the ISI Science Citation Index (1990-present) to identify subsequent studies that had referenced them. We did not search for abstracts, unpublished studies nor other such literature as the data reported are often preliminary and may not be representative of the final study result [15] . The search was not limited to studies published in English. We read the abstracts of all identified studies to exclude those that were clearly not relevant. The full texts of the remaining articles were read to determine whether they fulfilled the study inclusion criteria. Eligible studies were also identified by hand searching the reference lists of retrieved articles, including reviews.
Study selection
We included all studies that were based on cohorts of patients diagnosed with RA that enabled a quantitative assessment of the risk of melanoma in RA patients treated with TNFα biologics compared with those treated with nbDMARDS or the general population. Studies that reported different measures of relative risk, namely, hazard ratio, odds ratio, and SIR, were included. We excluded randomized-controlled trials (RCTs) because they are typically conducted using small numbers of participants over a short duration and for rare outcomes such as melanoma, larger sample sizes and longer-term follow-up are required. RCTs also have strict inclusion criteria, making it difficult to generalize the trial findings to other more heterogeneous patient populations. Finally, screening of potential patients before (and surveillance during) clinical trials may eliminate patients at highest risk of developing melanoma in the short term or alternatively could result in surveillance bias.
Any discrepancies between investigators on inclusion of a study were resolved by joint evaluation of the manuscript. When multiple reports were published on the same population or subpopulation, we included in the meta-analysis the report with the longest follow-up duration or the most comprehensive data.
Data extraction and quality assessment
Two investigators (C.O., L.K.) independently abstracted data from identified studies using a standardized data abstraction form, with inconsistencies resolved by consensus. The following information was recorded for each study: study design, location, years of data collection, source and definition of cohort, number of cases, personyear duration of follow-up, age of the study population, variables used for statistical adjustment, point estimates (odds ratio, hazard ratio, or SIR) and 95% CI. We evaluated the quality of primary studies using the Newcastle-Ottawa Scale [16] , a validated technique for assessing the quality of observational studies.
Data synthesis and analysis
To pool individual study estimates for the risk of melanoma in RA patients, we used the method of DerSimonian and Laird [17] using a random-effects model. Statistical heterogeneity among studies was assessed using the Q-statistic [18] (significance level at P < 0.10) and inconsistencies were quantified using the I 2 statistic [19] . We carried out a sensitivity analysis by excluding one study at a time and calculated the pooled relative risk for the remaining studies to evaluate whether the results could have been affected markedly by a single study. Finally, publication bias was evaluated through visual inspection of a funnel plot and using Begg's and Egger's tests [20, 21] . We calculated the absolute risk of melanoma in RA patient treated with TNFα biologics in several populations (USA, UK, Denmark, Sweden, Australia) using age-standardized incidence rates sourced from Globocan 2012 [22] . All statistical analyses were carried out using Stata, version 10 (Stata Corporation, College Station, Texas, USA).
Results

Search
Details of the selection process for the eligible studies are shown in Fig. 1 . Of 812 titles identified, a total of six studies eligible for inclusion in our systematic review were identified [3, 4, 11, 12, 23, 24] ; four studies reported an estimate for the risk of melanoma in RA patients treated with TNFα biologics compared with those treated with nbDMARDS [3, 4, 23, 24] and five reported an SIR for the risk of melanoma in RA patients treated with TNFα biologics compared with the general population [3, 11, 12, 23, 24] . Two studies included patients treated with Anakinra [an interleukin-1 (IL-1) receptor antagonist] in their bDMARD cohorts; however, this constituted only 2 [11] and 2.5% [3] of included patients, and the latter study reported results for individual drugs in their comparison with the nbDMARD treatment group (not, however, in their comparison with the general population). One study presented estimates for different types of TNFα biologics (etanercept, infliximab, adalimumab) [3] .
Characteristics of the studies included
The main characteristics of the studies included are listed in Table 1 . Studies were published between 2005 and 2015. Three studies were carried out in Northern Europe [4, 12, 23] , two in North America [3, 11] and one in Australia [24] . The mean or the median follow-up duration for the cohorts ranged from 2.1 to 4.8 years. Two studies reported on overlapping cohorts [4, 12] ; however, each reported a different comparison (i.e. in the study reported by Askling et al. [12] , the comparison group was the general population whereas for Raaschou et al. [4] , the comparison group was RA patients treated with nbDMARDS), and thus both were included in the review. With the exception of one study that relied on administrative claims data [11] , all melanoma diagnoses were established through linkage with cancer registries. Only one [3] of the four studies [3, 4, 23, 24] that reported on the risk of melanoma in RA patients treated with TNFα biologics compared with patients treated with nbDMARDS had adjusted for a measure of disease severity at baseline.
Quality assessment
Five [3, 4, 12, 23, 24] of the six studies scored 8 out of a possible score of 9 using the Newcastle-Ottawa quality assessment scale for cohort studies [16] ; the remaining study scored 7 points [11] .
Outcome
The pooled effect estimate for studies reporting on the risk of melanoma in RA patients treated with TNFα biologics compared with RA patients treated with nbDMARDS was 1.60 (95% CI 1.16-2.16) ( Fig. 2 ). Exclusion of one study at the time resulted in summary estimates ranging from 1.50 (95% CI 1.07-2.11) with the omission of Wolfe et al.
[3] to 1.78 (95% CI 1.04-3.05) with the omission of Raaschou et al. [4] . There was no evidence of publication bias (Begg P = 0.45; Egger P = 0.72).
The pooled SIR for studies reporting on the risk of melanoma in RA patients treated with TNFα biologics compared with the general population was 1.87 (95% CI 1.53-2.30) (Fig. 3) . The summary estimate was not materially influenced by excluding one study at a time, with the pooled SIR ranging from 1.71 (95% CI 1.34-2.18) with the omission of Setoguchi et al. [11] to 2.07 (95% CI 1.55-2.77) with the omission of Wolfe et al. [3] . Again, there was no evidence of publication bias (Begg P = 0.46; Egger P = 0.38). There was no significant heterogeneity for either analysis (Figs 2 and 3) .
In absolute terms, the increased risk would equate to an estimated additional 12 cases per 100 000 RA patients treated with TNFα biologics per year in the USA, 16 in Denmark or Sweden and 30 in Australia above what would be observed in the general population.
Discussion
We have examined the available evidence from observational studies reporting on the risk of melanoma in RA patients treated with TNFα biologics and report a 60% increased risk compared with patients treated with nbDMARDS and a 90% increased risk compared with the general population.
A previous meta-analysis for the comparison with patients treated with nbDMARDS [6] had pooled the results of two studies, an interim report from the Swedish biologics register [Antirheumatic Therapy in Sweden (ARTIS)] [25] and a report by Wolfe and Michaud [3] using data from the US National Data Bank for Rheumatic Diseases. The combined estimate of those two studies was 1.79 (95% CI 0.92-2.67) [6] . Our meta-analysis extends that analysis by including a more recent report from the ARTIS study [4] (including an additional 31 530 person-years after TNFα biologics treatment) as well as a report from the national Danish DANBIO database [23] (15 592 person-years after TNFα biologics treatment) and the Australian Rheumatology Association Database [24] (5752 person-years after TNFα biologics treatment), resulting in a more precise risk estimate. A combined estimate from observational studies of the risk of melanoma in RA patients treated with TNFα biologics compared with the general population has not been reported previously. Notably, our findings are not discordant with a pooled analysis of 36 RCTs examining the risk of melanoma in RA patients treated with Adalimumab compared with the general public, which reported a pooled SIR of 1.5 (95% CI 0.84-2.47) [26] .
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with nbDMARDS, but the observational data, in aggregate, suggest an increased risk of keratinocyte skin cancers [28] as well as melanoma [6] . The role of TNFα antagonist treatment in cancer development is complex as it exerts both procarcinogenic and anticarcinogenic effects [7] . TNF may promote tumour development and progression through inflammatory pathways [29] , but it is also involved in the immunosurveillance of cancer cells [30] .
All studies included in our meta-analysis received a highquality score using the Newcastle-Ottawa quality assessment scale for cohort studies [16] . A limitation of our analyses was the potential for publication bias. Our analyses may have been subject to publication bias because we did not search for unpublished studies, abstracts nor other such literature but, in contrast, inclusion of results from only peer-reviewed studies ensured greater assurance of the quality of those data that we did include. Several studies that examined cancer outcomes in a cohort of RA patients treated with TNFα biologics were not eligible for inclusion in our review because they did not provide an estimate of the association for melanoma. Two of these reports [31, 32] that examined risk in a TNFα biologics-treated group compared with an nbDMARD-treated group reported a melanoma case in the treatment group, but not in the comparison group. A third report that compared incidence rates in a TNFα biologics group (n = 1114) compared with the general population did not report any melanoma cases in the treatment group [33] after an average follow-up duration of 23 months. Two other excluded studies [34, 35] reported on solid cancers overall, but it was not clear from these reports whether melanomas cases were specifically assessed; this may have led to outcome reporting bias [36] if melanoma cases were observed but not analysed or reported because of nonsignificant or null results, resulting in an overestimate of a more modest true association. Conversely, the studies that were included in our review may not have sufficiently covered the latent period for melanoma development, with a maximum median follow-up period of 4.8 years, and this may had led to an underestimation of the association.
A further limitation of registry-based reporting is the challenge of full case ascertainment as well as case verification. Two of the studies included [3, 11] ascertained melanoma diagnosis using different methods for the RA cohort and the comparison population (i.e. internal ascertainment for the RA cohort and registry ascertainment for the general population comparison), which may have led to more complete case ascertainment in the RA population. The remaining studies used linkage to national cancer registries for both the RA cohort and the comparison population. Our findings may not be generalizable to all populations as the combined estimates were heavily weighted by the results of studies carried out in the USA and Sweden, and furthermore, under-registration of melanoma is a limitation of the US National Cancer Institute, Surveillance, Epidemiology and End-Results (SEER) data (estimates range from 30 to 40%) [37] . Finally, limited control of confounding may have influenced the results as all except one of the studies included [4] did not have information on key melanoma risk factors such as skin type, ethnicity, prevalence of melanocytic nevi nor family history. These factors, however, are not associated with RA and are thus unlikely to have influenced the observed associations.
Only one [3] of the four studies [3, 4, 23, 24] that reported on the risk of melanoma in RA patients treated with TNFα biologics compared with patients treated with nbDMARDS had adjusted for a measure of disease severity at baseline and only two studies [23, 24] reported sufficient data to determine baseline differences in disease severity between the comparison groups. Although a positive association has been reported for RA disease severity and the risk of lymphoma [38] , however, it has not been reported for melanoma and thus is unlikely to have influenced the associations observed.
In conclusion, analogous to other immunosuppressed patient groups, RA patients treated with TNFα biologics appear to be at an increased risk of melanoma and therefore may benefit from regular screening of the skin for suspicious pigmented lesions. It remains unknown whether treatment with TNFα biologics increases the recurrence rate of melanoma or the risk of second primary in those with a previous melanoma; to date, there is only anecdotal information from case series [39] . Further large-scale cohort studies with patient-level clinical data have the potential to better inform the management of the risk of melanoma in RA patients treated with immunosuppressive therapies by better understanding the impact of immunosuppression, as well as how known risk factors operate differently in these populations versus the general population.
